Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

VK0214

Small molecule · developed by Viking Therapeutics

Phase 1 Most advanced trial (none active)
VKTX Developer
1 Registered trials

What is VK0214?

VK0214 is an investigational small-molecule drug studied in Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD).

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Viking Therapeutics, Inc. (VKTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
6FGG71NJ3Y

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04973657 Phase 1 Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) Completed VKTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

More from Viking Therapeutics

VK2735 Investigational VK2809 Investigational VK5211 Investigational

Follow VKTX, the company behind VK0214

See VKTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VKTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.